Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nanvuranlat (Primary)
Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms JPH203-SBECD-P2
Sponsors J-Pharma

20 Jan 2024 Results of ad-hoc analysis, classifying BTC patients by NAT2 phenotype , analyzing clinical efficacy and safety in the NAT2 NR population, presented at the 2024 Gastrointestinal Cancers Symposium
06 Jun 2023 Results of subgroup analysis assessing effect of level of expression of LAT1 on nanvuranlat efficacy presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
21 Jan 2023 Primary endpoint (Progression Free Survival (PFS) by blinded independent central review) has been met as per results presented at the 2023 Gastrointestinal Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com